Company Description
Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally.
The company offers High Velocity Therapy systems, such as HVT 2.0, Precision Flow Hi-VNI, Precision Flow Plus, and Precision Flow Classic which delivers non-invasive ventilatory support to patients by providing heated, humidified, and oxygenated air at a high velocity to treat patients through a small-bore nasal interface.
It also provides companion products, including Vapotherm Transfer Unit, which allows patients to be transferred between care areas within the hospital or ambulate while on therapy; Q50 compressor that provides compressed air necessary to run the precision flow systems in areas of the hospital without access to a wall gas source; aerosol aeroneb adaptor to facilitate delivery of aerosolized solutions; aerosol disposable patient circuit that is designed to streamline the provision of continuous and intermittent delivery of aerosol solutions for patients; and tracheostomy adaptors that simplifies the connection of the High Velocity Therapy systems to a tracheostomy collar used to wean patients off mechanical ventilation.
In addition, the company offers ProSoft cannula to provide gentle contact with the skin; and disposable products comprising single-use disposables and nasal interfaces, as well as Oxygen Assist Module, which helps clinicians maintain oxygen levels within a target range.
Vapotherm, Inc. was founded in 1993 and is headquartered in Exeter, New Hampshire.
| Country | United States |
| Founded | 1993 |
| IPO Date | Nov 14, 2018 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 182 |
| CEO | Joseph F. Army CPA |
Contact Details
Address: 100 Domain Drive Exeter, New Hampshire 03833 United States | |
| Phone | 603-658-0411 |
| Website | vapotherm.com |
Stock Details
| Ticker Symbol | VAPO |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001253176 |
| CUSIP Number | 922107107 |
| ISIN Number | IE0003LFZ4U7 |
| Employer ID | 46-2259298 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Joseph F. Army CPA | Chief Executive Officer, President and Director |
| John Landry | Senior Vice President, Chief Financial Officer and Treasurer |
| Brian Lawrence | Senior Vice President and Chief Technology Officer |
| William Niland | Founder |
| Dorota Mckay | Vice President, Controller and Chief Accounting Officer |
| Anthony Ten Haagen | Vice President of Legal and Compliance |
| James A. Lightman | Senior Vice President, General Counsel and Secretary |
| Lindsay Becker | Vice President of Human Resources |
| Dr. Jessica Whittle M.D., Ph.D. | Chief Medical Officer and Vice President of Clinical Research |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 1, 2024 | 8-K | Current Report |
| Feb 27, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 27, 2024 | 8-K | Current Report |
| Feb 22, 2024 | 10-K | Annual Report |
| Feb 22, 2024 | 8-K | Current Report |
| Feb 15, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |